Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J’s Clinical Data Disclosure Strategy Focuses On Collaboration With Yale University Group

This article was originally published in The Pink Sheet Daily

Executive Summary

In what appears to be the most expansive policy to date on release of clinical trial data, J&J will use an existing outside group and will share full clinical study reports and patient-level data regardless of when the studies were conducted.

You may also be interested in...

Clinical Trial Data Sharing: Central Public-Private Portal May Expand Access

J&J has gotten 25 requests for data through YODA project; BMJ study ranks GSK, J&J, Pfizer highest in making data publicly available and Gilead lowest.

BIO 2015 Dispatches: Data Transparency Initiatives Could Deter Industry Investment, Attorney Says

Covington partner Richard Kingham says early disclosure of clinical data could impede sponsor efforts to secure patents, driving away potential investors in the process. But EMA's Hans-Georg Eichler says investors should welcome the initiatives because they will bring greater efficiency to drug development.

Clinical Trial Transparency Gets A Boost With J&J Agreement, IOM Report

Johnson & Johnson's device and diagnostic clinical trial data is now available to independent researchers via Yale University’s Open Data Access (YODA) Project, announced the same day as an Institute of Medicine report mapping out strategies for clinical trial data-sharing.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts